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ABSTRACT
The primary goal of this internship is to explore the financial impact of changing one or
more of the downstream chromatography steps involved in the purification of a complex biologic
molecule from a batch process to a continuous one. This is particularly relevant, as biologics
represent the fastest growing segment of the human therapeutics market, and, consequently, have
become a major component of most large pharmaceutical companies, such as Novartis.'
Specifically, I examined the Multicolumn Countercurrent Solvent Gradient Purification
(MCSGP) system, a continuous chromatography unit produced by ChromaCon, in the first part
of the internship.2 By collecting and analyzing data from previous experiments done with this
technology, I was able to estimate the potential benefits in the production process of Biologic X.
Then, after evaluating the current cost structure of this molecule, I determined the reduction in
COGS associated with the successful implementation of MCSGP.
In the second part of the internship, I examined the downstream purification of another,
more complicated molecule. I studied each individual step, and then modeled each one as if it
were continuous. For the chromatography steps, I applied either the MCSGP, or another
continuous technology developed by Novasep, the BioSC process. Other key steps, such as the
specific enzymatic reactions that are currently done in large batch reactors, were also modeled as
continuous processes.
I was able to show that with the MCSGP technology, the COGS of the drug substance
(DS) of Biologic X could be decreased by 25%, with a resulting eNPV of savings of >$25M.
Furthermore, I determined that: 1) MCSGP has a significant developmental risk, but it has
considerable cost savings because it can increase product yields, and 2) BioSC has less
developmental risk, and it can significantly decrease costs of high throughput products that
require large amounts of expensive resins and buffers.
There are clearly significant benefits to be gained from continuous chromatography
technologies. One must weigh the developmental risks with the financial benefits, keeping in
consideration the regulatory implications of changing manufacturing methods. The end result of
this work will hopefully translate into higher margins and profits for Sandoz Biopharmaceuticals.
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CHAPTER 1
BACKGROUND
1 Background
1.1 Sandoz and Novartis
In 1996, Sandoz and Ciba-Geigy merged to form the large pharmaceutical giant known
today as Novartis. The two predecessor companies were themselves well diversified before the
merger:
e Ciba-Geigy was involved in many different industries, including pharmaceuticals,
chemicals, and materials.
" Sandoz also had a very diverse portfolio of products, including pharmaceuticals,
chemicals, agricultural products, and consumables such as baby food.
After the merger between Sandoz and Ciba-Geigy, the pharmaceutical branches of these
two companies combined efforts, and many of the other divisions were spun-off into different
business entities. The two companies joined their generic drug divisions and named that separate
branch Sandoz. So, whereas the Sandoz company that was known before the merger was a
multi-faceted corporation, after the unification it became the generics company of Novartis.
Sandoz is one of the many different segments of Novartis, which also includes the
following:
* Pharma (pharmaceuticals)
e Generics (Sandoz)
e Consumer Health
" Vaccines/Diagnostics
e Alcon (recently acquired ophthalmology-focused pharmaceutical)
Of the $44.3B revenue that Novartis achieved in 2009, $7.5B was derived from Sandoz
products. Of the 100,000 employees that serve Novartis companies, 23,000 are Sandoz
employees. Clearly, Sandoz does represent a significant portion of Novartis' business. In
addition, as the patents of many biologic molecules (complex therapeutic molecules that are
made from microorganisms or human cells that are genetically engineered to produce these
molecules; the complexity of these therapeutics does not allow for their chemical synthesis)
expire in the coming years, and the biosimilar (the generic version of biologic molecules)
registration pathway becomes more clear-cut in the United States, Novartis will rely on Sandoz
to lead those efforts. The market for biosimilars is estimated to be $19.4B by 2014.3 Sandoz is
already the world leader in biosimilars, with three approved drugs on the market: Binocrit (a
generic version of Procrit, a biologic that increases red blood cell production), Omnitrope (a
generic version of growth hormone), and Zarzio (a generic version of filgrastim - a granulocyte
colony-stimulating factor, or G-CSF, used to increase white blood cell production).
1.2 Continuous Manufacturing and MIT
The pharmaceutical industry, due to cost pressures from increased global competition and
reduced reimbursement rates, has had to focus its attention on operational processes. Whereas
before these companies were able to enjoy the most profitable returns of any industry, allowing
them to forgo operational excellence, their margins are now decreasing and the optimization of
their manufacturing processes has become paramount. 4
The industry has traditionally used batch processes for the production of pharmaceutical
agents. This is because of the ease of segregating products into lots; the relatively smaller
amount of product manufactured compared to other industries, such as chemicals; and the batch-
nature of the biomedical laboratories from which these chemicals are first synthesized.5
However, recently, there has been a significant effort to create continuous processes that allow
for decreased inventory and increased process control.6 In fact, MIT has recently entered into a
multi-million dollar collaboration with Novartis to establish a continuous manufacturing process
for pharmaceuticals. 7 More specifically, the 65 million dollar investment will span over ten
years, and is officially titled the "Novartis-MIT Center for Continuous Manufacturing." This
collaboration will aim to improve the supply and quality of drug products, as well as reduce the
environmental impact of drug development and production. Ten MIT faculty members, as well
as numerous students, Ph.D. candidates, postdoctoral fellows, and staff scientists are working
side-by-side with their Novartis counterparts.
This collaboration, however, involves the manufacturing of small molecule drugs, not
biologics. This is because small molecules (pharmaceutical agents like acetaminophen, which
are synthesized from chemical processes) have been in production for a longer time than most
biologics, like monoclonal antibodies and cytokines, allowing their manufacturing processes to
be better understood and refined. With the first biologic, Eli Lilly's recombinant insulin product
Humulin, approved in 1982, these larger molecules have a much younger history.8 Similarly,
continuous manufacturing of biologic molecules is still in its infancy.
1.3 Biologics and their presence at Sandoz and Novartis
Biologics represent the fastest growing segment of the human therapeutics market, and as
such has become a major component of most large pharmaceutical companies, such as Novartis.9
Whereas before, these behemoth companies were able to focus solely on small compounds, they
can no longer ignore the profitability of large molecules. Indeed, Enbrel, Remicade, and Avastin
were able to gross $8B, $6.9B, and $5B in sales in 2009, respectively.10
Novartis has increased its presence in the biologics space by developing and licensing
numerous molecules, such as ranibizumab (Lucentis, co-marketed with Roche) and omalizumab
(Xolair). Similarly, Sandoz Biopharmaceuticals continues to hold a strong presence in the
growing biosimilar market.
With increased attention placed on follow-on biologics, as the US government and
regulatory officials carve a path for their registration and approval process, companies like
Novartis and Sandoz Biopharmaceuticals are investing a significant amount of capital in
technologies to improve their production processes. The increased scrutiny that will be placed
on these biologically-derived compounds, coupled with the cost pressures resulting from recent
healthcare legislation, will undoubtedly force companies to devise manufacturing methods that
are both robust and cost-efficient. Currently, many pharmaceutical companies are creating
continuous production techniques that allow for greater process control and decreased
inventory."
The production of a biologic molecule can be separated into two major groups of
processes: upstream and downstream (see Figure 1).
e The upstream process is mainly involved in the actual production of the molecule. Cells,
either human or microbial, are genetically engineered to produce the peptide or protein of
interest. This is done by modifying the genetic material, the DNA, of these cells so
certain genes are expressed. After a predetermined time or number of cellular life cycles,
the media containing the cell and protein products is then sent for downstream
processing. This solution is quite impure, as it contains much cellular debris, such as
DNA, cellular membrane proteins, fragmented products, aggregated products, and host
cell proteins. The process of producing these proteins is usually a batch process;
however, there are technologies, such as the perfusion bioreactor, that allow for the
continuous production of biologics.
* The downstream process is mainly involved in the purification of the upstream feed and
the further processing of the product. For the former, numerous purification methods are
available: specialized filters, centrifugation, and chromatography are a few popular ones.
This project focuses on chromatography, a process by which a solution containing a
product is passed through a column containing specialized resin beads. These beads have
special properties that allow for the specific binding of the protein of interest, while the
impurities flow out of the column. Then, the product is eluted, or removed, from the
resin with a specific eluent fluid. There are specific chromatography technologies
available in which impurities bind the resin beads, and the product of interest flows right
through the column (flow-through chromatography). Other downstream processes
include enzymatic and refolding reactions that ensure the biologic has the correct
composition and structure - they are beyond the scope of this thesis. Once the product
has been adequately purified, it is known as drug substance, which is then further
processed (dried, packaged, labeled) to become the drug product that is ultimately
distributed and sold.
Upstream processes
D~ownstream prcesses
DRUG SUBSTANCE
Figure 1. Typical schematic of upstream and downstream processes
As mentioned earlier, one of the key steps involved in the purification of biologics is
chromatography. This has traditionally been done in a batch fashion, although there have been
some technological advances that permit continuous processing. 13 Limitations of these newer
methods include their difficult implementation and the binary nature of their output streams.
Regarding the latter, with only two output flows, these technologies often cannot achieve the
pure product extraction that traditional batch processes typically yield. However, recently a
Swiss company (ChromaCon) was able to develop a system that allows for continuous
chromatography and produces three output streams. This technology is called the Multicolumn
Countercurrent Solvent Gradient Purification (MCSGP) system. It is very early in development,
with only laboratory scale equipment available, but early data show that it can increase
chromatography step yields dramatically.14
1.4 The Internship and Objectives
When the internship at Sandoz, specifically the Kundl plant, was proposed, the project
was introduced through Novartis, as Sandoz Biopharmaceuticals had not been created. The
actual proposal, though, was written by the management in Kundl, specifically Dr. Andreas
Premstaller and Dr. Klaus Graumann.
" Specifically, for the first part of my project, they were interested in exploring the
aforementioned MCSGP technology for a low yield step involved in the purification of
Biologic X. The technology is considerably risky, as it only exists in laboratory-scale,
but the initial studies are promising. Given the projected loss of product and the cost
associated with the current chromatography method, Sandoz is interested in an
improvement process. Thus, the first part of my internship centered around the following
topic: Determine the financial effect and associated risks of utilizing the MCSGP
technology in the downstream purification of Biologic X. This would require making a
financial model that would translate potential increased product yields to lower
production costs.
" In addition to the first goal, Sandoz is interested in exploring a fully continuous
downstream purification process (they want to maintain the upstream batch processes,
even though there are continuous perfusion bioreactors at different Sandoz sites). They
have a specific product, Biologic Y, which they wanted me to explore, as construction of
a greenfield plant may be required to satisfy future demand. The development of this
product is a collaboration between Sandoz and Novartis, so there is much interest
throughout the organization. The downstream purification process of Biologic Y is much
more complicated than that of Biologic X, and it requires a number of chromatography
steps and enzymatic reactions, as well as a lyophilization step. The main goal of the
second part of my internship was to address the following topic: Determine thefinancial
impact of creating a production line for Biologic Y that has a completely continuous
downstream purification process. To do this, I will utilize relevant parts of the model
created in the first part of my internship, as well as new ones. For example, for some of
the chromatography steps I will also explore other technologies, such as the BioSC
process by Novasep (to be described in Chapter 3). In addition, the enzymatic reactions
will be modeled as tubular reactors that could ensure a continuous flow. The
lyophilization process was left in its current process, as it is beyond the scope of my
project, and could be explored by another internship.
CHAPTER 2
INTRODUCTION TO CURRENT PROCESSES
2 Current Processes
2.1 General Concepts
For the purpose of this thesis, I will provide as many details as possible, so as to make
this as helpful as possible. However, most of the products that Sandoz is developing are not
public knowledge. This is especially true with the follow-on biologics, or biosimilars, as this
market is similar to the generics market for small molecule therapies. The main reasons for not
disclosing the products in development are the following:
1. First-mover advantage among biosimilars. Just as generics that are first to market derive
an economic benefit, so too will a developer of a follow-on biologic. These benefits are:
a. The first generic/biosimilar to the market will be the first one adopted by
prescribers and payers. This will have the effect of establishing brand loyalty, as
patients and doctors often become reluctant to keep switching different drug
products.
b. The first generic/biosimilar to market will enjoy a certain period of exclusivity.
For small molecules, the first generics company to get its version of a drug
approved typically gets 180 days of market exclusivity after the original drug
patent expires.15 During this time no other generics company can market their
copy of the drug. The pathway for biosimilars is still very early, but according to
the Biologics Price Competition and Innovation Act of 2009, the first biosimilar
will receive at least one year of exclusivity, during which time other biosimilars
cannot be marketed.16
2. Prevention of broad interest. Sandoz does not want other companies to know which
biologics it is pursuing, and at what stages they are in. Indeed, if other companies
discover what compounds Sandoz is pursuing, they might decide to pursue them as well.
The addition of more competitors would decrease the potential market share that Sandoz
could enjoy.
3. Prevention of countermeasures by the originator company. The author believes
originator companies are quite wary of the potential entrance of biosimilars. Should one
of these companies become aware of a potential competitor, it would likely launch a pre-
emptive publicity campaign against the proposed biosimilar. In fact, originator
companies have already started warning doctors and patients that biosimilars are not the
same as the original compounds, and that this difference can be harmful.
For all of these reasons, I will take guarded measures so readers of this thesis cannot infer
the molecules I examined. The following sections describe very common upstream and
downstream processes used in the production of biologic molecules.
2.2 Upstream Production
2.2.1 Mammalian Cell Culture
Biologics are currently produced through recombinant techniques very common in the
biotech industry. More specifically, the genes can be carefully inserted into the genome (DNA,
or genetic material) of Chinese Hamster Ovarian (CHO) cells (mammalian cells). Figure 2
shows how recombinant technology is utilized to create cells that can express the protein of
interest.
4C* Protein of interest
Cytoplasm
Genetic sequence to be Proteinof inte
inserted into CHO cell DNA 0
Nucleus
CHO cell DNA CHO cell expressing protein of interest
Figure 2. Recombinant technique for mammalian cells' 7
These cells are then screened to make sure the inserted gene is in the correct position,
after which they are grown in specific growth media. During this time, they are constantly
multiplying and producing the protein of interest through transcription in the nucleus, and
subsequent translation in the cytoplasm. Figure 3 shows how genes are transcribed from DNA
to RNA in the nucleus, and then translated from RNA to proteins in the cytoplasm.
Figure 3. Transcription and translation of a gene' 8
These genetically altered CHO cells are cultured into larger and larger media tanks, in
which they are induced to produce more protein. The growth time is optimized so that the
maximum amount of protein is extracted from this solution before there is significant cell death
and degradation of the desired proteins. After this growth or harvest phase, the proteins are
ready to be collected and purified - this occurs in the downstream purification process.
2.2.2 Microbial Cell Culture
Just as proteins are made in mammalian cells, they can also be produced in other cells,
such as microbes. In fact, this technique is very widespread, as many biologics are produced in
the common bacterium Escherichia coli (E. coli). Although methods in mammalian and bacterial
cells are similar, the downstream purification processes of the latter are often complicated by the
fact that the protein products often require re-folding steps. This is because the bacterial
(microbial) cells often do not have the same internal machinery that allows mammalian cells to
completely process the proteins before they are released. However, growing and harvesting
proteins from microbial cells can be advantageous in that they are easier and cheaper to culture,
they are not as vulnerable to contamination, their growth times are much quicker, and they are
able to produce higher product titers (amounts). Indeed, determining which cell type to use can
be quite challenging. As each protein product has its unique set of characteristics, one must
weigh the pros and cons on an individual basis, and then decide which cell line will yield the best
results. The techniques for inserting the desired gene products into the microbial cell's DNA is
very similar to those involved in mammalian cells (section 2.2.1).
2.3 Downstream Purification
After the proteins from the upstream production step have been collected, the protein of
interest must be purified. This can be a challenging task, as there are many proteins and cellular
debris in the solution, which include:
" Host cell proteins (HCPs) - these are proteins that are normally produced by CHO and
microbial cells that must now be separated from protein of interest.
" Degraded products - some of the target proteins will be degraded during the process.
Removing these presents a significant challenge, as they have many similar
characteristics as the protein of interest.
" Aggregated product - some of the target proteins will aggregate in such a way as to
become non-usable. Similar to the degraded products, they are often difficult to remove,
as they too have similar characteristics as the protein of interest.
* DNA and other molecules - these also must be removed before a final drug product can
be produced.
There are many methods that are utilized to purify biologics. Several key processes will
be discussed below - these are general methodologies that are meant to help the reader
understand the rest of the thesis. The list is not comprehensive, as there are other techniques,
such as centrifugation, precipitation, and crystallization, which are commonly used as well.
However, the following processes will be most helpful when reading chapters 3-5:
* Filtration: There are numerous types of filters that are utilized in the separation process
of biologics. The step yields (their significance to be described later in Chapter 4) are
generally pretty high at >90% (less than 10% of the product is usually lost). Common
methods of filtration are the following:
o Ultrafiltration: This process is used to remove large molecules/impurities. The
solution is forced through a semi-permeable membrane (filter) which collects
large impurities, allowing the protein of interest to pass through.
o Diafiltration: This process is used to remove small molecules, such as exchange
salts (used in chromatography), from the solution of interest. Solvent is typically
added to the solution, which is then passed tangentially across a filter which
collects/traps the small impurities as they go by the semi-permeable membrane,
allowing the larger protein molecules to pass. This is done several times to
achieve a desired purity. This type of filtration is also known as tangential flow
filtration.
o There are other common filtration methods, such as nanofiltration and
microfiltration, but they are similar to the ones described above.
e pH adjustment: During the course of the downstream purification process, the pH of the
solution is often adjusted. By adding either acidic compounds, such as hydrochloric acid
(HCl) or sulfuric acid (H2SO 4), or basic compounds, such as sodium hydroxide (NaOH)
or potassium hydroxide (KOH), the pH of the solution can be adjusted accordingly. This
is important, as certain chromatography steps require the solution to be within a certain
pH range. In addition, proper protein folding is also dependent on the pH of the solution.
Finally, changing the pH can help kill off any potential viral contaminants.
* Chromatography: This is a very common separation process that is used in many
different industries. Small resin beads, typically agarose or polyacrylamide, contain
surface properties that allow for the binding of specific molecules. These can either be
the molecules of interest, or the impurities that need to be removed. In the case of the
former, a solution containing the protein of interest is pumped through the resin, resulting
in the protein binding to the resin. There are very specific conditions, such as the pH and
polarity of the solution, that allow this interaction to take place. Then, after the
impurities have washed through the resin column, another solvent, the eluent, is used to
remove the proteins off of the resin. Again, solution properties, such as the pH, are
critical to allow for the dissociation of the protein from the resin. This common motif is
known as a "bind and elute" mechanism, and is shown in Figure 4. Specific
chromatography processes include the following:
o Ion exchange chromatography. Ion exchange chromatography is a very common
chromatographic technique.19 It takes advantage of the different charges of the
molecules to be separated. This method is divided into two main categories:
- Cation exchange chromatography. In this method, the resins contain
negative charges, and so positively charged molecules are attracted to
them. As the positively charged molecules attach to the resins, the more
negatively charged molecules continue to flow through the column. It is
conventional for the protein of interest to be bound to the resin, while
impurities pass through.
- Anion exchange chromatography. In contrast to cation exchanges, the
resins in this method are positively charged. Thus, they attract anionic
(negatively charged) molecules, allowing the positive ones to pass freely.
o Flow through chromatography. This is a variation of chromatography in which
the molecule of interest is allowed to pass through the column while the impurity
that is being isolated binds to the resin. In this way, the initial flow stream is the
product stream, and the eluent removes the impurities from the resin.
o Affinity chromatography. Affinity chromatography takes advantage of how
strongly certain molecules are attracted to each other.20 This can be the result of
the complex interaction of an antibody and its antigen, or a receptor and its
ligand.
- Protein A chromatography: This is a chromatographic method that is
mainly used when purifying monoclonal antibodies. In this case, the resin
beads have many particles of Protein A attached to them. Protein A is
unique in that it is able to bind mainly to the Fc (fragment, crystallizable)
portion of the monoclonal antibody with great specificity and potency.
So, when a solution containing monoclonal antibodies is passed through a
column with Protein A resin, the antibodies bind to the resin, while the
impurities pass through. Resins that contain Protein A are very expensive,
but they are very effective as well.
Hydrophobic interaction chromatography: This chromatographic method,
otherwise known as HIC, takes advantage of the hydrophobic surface
properties of the molecule of interest. The HIC resin beads contain
hydrophobic surface areas that allow binding of these hydrophobic facets.
For this to be successful, the correct conditions, such as the pH and salt
concentrations, must be carefully applied.22
o Size exclusion chromatography. Size exclusion chromatography, also known as
SEC, is another broad category of chromatography that is commonly used. In this
method, the resin is very porous, and smaller molecules traveling down the
column spend much time in these porous structures. Larger molecules,
conversely, cannot enter these pores, causing them to flow down the column at a
faster rate. In this way, larger molecules are able to be separate first from the
smaller molecules that follow after them.23
Solution with product Eluent
and impurits
Resin wit product
protein bound
Solution with Eluent with protein
Bind Elute
Figure 4. Typical bind and elute chromatography
e Enzymatic reactions. As mentioned previously, there are certain post-translational steps
that are performed in mammalian cells that are not done in microbial cells. These could
include re-folding (to ensure the protein will have the correct shape so it can perform its
required actions) reactions, or the addition of certain groups (such as a methyl group).
The particular reactions are not described in this document, and are not pertinent to the
objective of this thesis. It is only required to know that these reactions are necessary for
the production of the drug substance.
* Lyophilization. Lyophilization, also known as freeze drying, is a very costly and time-
consuming process in which proteins in a liquid solution are basically dried to form a
powdery drug substance. This is a complicated process, as biologics are not stable, and
are very sensitive to high temperatures - they degrade very quickly. The basic steps of
freeze drying include the following:
o The solution is cooled/frozen in a low pressure environment (this facilitates the
evaporation of solvent at lower temperatures).
o The frozen bed of solution is then heated in this low pressure environment in such
a way as to allow for the sublimation (phase change from solid to gas) of the
solvent. The low pressure environment allows for the sublimation process at low
temperatures, preserving the proteins.
This thesis does not focus on the lyophilization and technologies that model it as a
continuous process (spray-drying), as they are very complicated, and merit their own separate
investigations.
CHAPTER 3
CONTINUOUS PROCESSES
3 Continuous Processes
3.1 Introduction
This chapter will focus on three general groups of continuous processes: continuous
chromatography technologies, tubular reactors, and spray drying. Although there are other
different continuous technologies being implemented in downstream purification, these are the
ones I focused on during my internship. In addition, although perfusion reactors, which permit
continuous harvesting of protein products in the upstream process, are interesting, they will not
be discussed in detail. The current batch process has its advantages (tested, reliable, familiarity,
and less vulnerable to contamination), but I believe that recent advancements in perfusion
reactors may make this new technology more viable. Indeed, new perfusion reactors are now
achieving titers similar to that of their batch counterparts.
3.2 Continuous Chromatography
3.2.1 MCSGP
The Swiss company ChromaCon has developed a novel technology that allows for
continuous chromatographic separations.2 This technique is called the Multicolumn
Countercurrent Solvent Gradient Purification (MCSGP) system. It is unique in that it is able to
generate three output streams, whereas other continuous systems typically have only two. In
addition, by generating these three streams, it is able to increase the overall yield of the process.
This can be extremely beneficial for low yield processes that lose much expensive product.
The actual mathematical description of this process is beyond the scope of this thesis,
which focuses on the financial impact of the technology. Furthermore, these mathematical
models have not been very useful in predicting the actual performance of the MCSGP on certain
processes. Rather, to more accurately determine the yield improvement achievable with this
process, empirical data is required through experimentation. For these reasons, only a general
description of the process will be included, which should be sufficient to understand how it
functions. The basic set up consists of three chromatography columns in series connected by a
complicated network of tubes and pumps. These allow for the two basic configurations that the
process alternates between, which allows for this separation advantage. Specifically, the steps
include the following:
1. During the first phase (see Figure 5), there are three feeds, one to each of the columns
that are labeled 1, 2, and 3. There are also three corresponding outputs. Light binding
impurities are colored blue, product streams are colored red, strong binding impurities are
colored green, feeds are colored brown, and the eluent streams are colored gray.
a. In column 1, the input represents the feed. When the feed enters this column,
which already contains strong binding impurities, product, and light binding
impurities, the light binding impurities are eluted out. The feed that enters the
column arranges itself in a gradient according to the binding properties of its
components: the light binding impurities travel furthest down the column, as they
are not slowed by interactions with the resins, while the strong binding impurities
travel the least down the column, as they are strongly attracted to the resin. The
actual desired protein product situates between these two extremes.
b. Simultaneously, in column 2, eluent is fed in, while the protein product is
expelled from the column and collected for further processing. Real-time
chromatographs (displays which show the composition of the outlet stream)
confirm the identity and purity of this stream.
c. Concurrently, in column 3, eluent is fed in while the strong binding impurities are
removed from the output stream.
d. Once a pre-determined amount of product is collected from column 2 (based on
content feed and real-time chromatographs), the three columns are rotated in a
direction counter to the input flows. Column 1 occupies column 2's position,
column 2 occupies column 3's position, and column 3 goes to column l's
position. Now the set up is ready for the second phase.
Eluent
3 2
Strong Binding Pro uct Feed Light inding
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Figure 5. Phase I of the MCSGP, three inputs and three outputs
2. With the three columns in their new positions, the tubing is switched so that there is only
one input and one output (see Figure 6).
a. Eluent is fed into column 2, which causes any protein product to be pushed into
column 1. Some of the strong binding product may leave column 2 and enter
column 1, but most of it should stay in column 2.
b. As the protein product enters column 1, the light binding impurities are forced
out, into column 3. Some protein product may leave column 1 and enter column
3, but the process is calibrated so that most of the protein remains in column 1.
However, all, if not most, of the light binding impurities must be forced to exit
column 1, because if much is left behind, the product stream during the next phase
will have low purity.
c. As the light binding impurities and some protein product enter column 3, more
light binding impurities exit this column
Eluent
2 3
Impurities
Figure 6. Phase 2 of the MCSGP, one input and one output
Eluent
3. The first phase is repeated, and the tubing is changed so that there are three inputs and
three outputs again (see Figure 7).
a. In column 3, the input represents the feed (similar to column 1 during the first
cycle). When the feed enters this column, more light binding impurities are
removed.
b. At the same time, in column 1, eluent is fed in, while the protein product is
expelled from the column and collected for further processing.
c. Concurrently, in column 2, eluent is fed in while the strong binding impurities are
removed in the output stream.
d. Once a pre-determined amount of product is collected from column 1 (based on
content feed and real-time chromatographs), the three columns are rotated in a
direction counter to the input flows. Column 1 occupies column 2's position,
column 2 occupies column 3's position, and column 3 goes to column l's
position. Now the set up is ready for the second phase of the second cycle. This
continues to repeat itself, and during the process, pure product is collected, while
light binding and strong binding impurities are removed.
Eluent Eluent
Strong Binding Pr uct Feed Light I inding
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Figure 7. First phase, repeated
4. As these phases repeat, the overall effect is that the side-streams that are normally
discarded during a batch chromatographic step, are recycled in such a way as to extract as
much protein product as possible. The side-streams are comprised of the mixtures where
the product is mixed with the light binding product or the strong binding product. One
can imagine that there is a mass of protein product that is increased and decreased in size
as feed is introduced and product is collected, respectively. On the tips of this mass are
areas where the protein is not pure; that is, it is contaminated by light binding or strong
binding impurities (see Figure 8). Thus, it is clear that by optimizing and then repeating
this process, the MCSGP process is able to extract more protein product and increase
yields significantly.
Strong-binding I Pure protein product I Weak-binding
impurity side- I to be collected I impurity side-
stream to be I I stream to be
re cycled recycled
Figure 8. Simple representation of protein product and impurities in MCSGP system
The MCSGP technology has an added benefit of requiring less buffer than conventional
chromatography columns. This aspect of the technology will be discussed in Chapter 5, as I will
not include the calculations in the first part of my thesis (to be discussed later).
3.2.2 BioSC
During the second part of my internship, there was more flexibility to study continuous
chromatography technologies other than the MCSGP. Whereas the MCSGP has the great
advantage of potentially increasing yields, it involves a significant developmental risk, as alluded
to earlier. In addition, there are current batch processes that already have very high yields
(>90%), for which the marginal benefit of this technology would be minimal. Thus, to model
other chromatography steps as continuous, I examined more technologies. More specifically, I
studied the BioSC Process that has been developed by Novasep.26 It is more advanced than the
MCSGP process - there are already large pilot-scaled projects that are able to run at rates of up
to 150 L/hour.
The BioSC process is similar to the Simulated Moving Bed (SMB) technology that is
utilized in many industries, such as the chemical industry. It has several advantages over current
batch processes:
1. The BioSC process increases the utilization of resin. This is critical, as resins, especially
those with Protein A, can be very costly. The mechanism by which the BioSC increases
resin utilization, or binding capacity, is as follows (this can be seen visually in Figure 9):
a. Instead of a single batch reactor, many reactors are arranged in series. With the
BioSC process, the current limit is six reactors.
b. As the feed goes through the first reactor, there is breakthrough of product, which
then goes to the next reactor. Breakthrough occurs when even the first column is
not fully "saturated" with the protein product. This is the time when typical batch
reactors stop loading a column, as the protein product is very expensive. Thus,
most companies would rather underutilize their resin binding capacity than lose
protein product. With the BioSC process, the first column can be loaded to
capacity without the risk of losing product, because it is flowing down to the other
columns.
c. Once the first reactor is fully loaded, it is eluted, washed, equilibrated, and then
brought back into the series of columns.
d. The increase in resin utilization, as reported by the company has ranged from
85%-140%. This is because there is a shift from a dynamic binding capacity
(with the current batch process) to a static binding capacity that is achieved with
the BioSC process. The actual increase in capacity can be predicted by studying
the breakthrough curves of the products with their specific resins and existing
conditions. This was not possible for this thesis, as we did not have the
breakthrough curves for Biologic Y. This is not that relevant, though, as this is
just an estimate, and must be followed with actual experimental data to determine
the true increased resin utilization benefit.
Figure 9. BioSC process
2. The BioSC process requires significantly less buffer and cleaning solutions. This is
process/step dependent, but the Novasep has shown a decreased consumption of 46%-
58%.27 This is noteworthy, as some buffers, especially those that contain the expensive
ingredient acetonitrile, can be costly if used in large quantities. In addition, if a company
is considering building a greenfield plant, decreased required buffer storage tank space
can result in significant savings.
3.3 Tubular reactors
This thesis will emphasize continuous chromatography technologies; however, as there
are several enzymatic reactions involved in the downstream purification of Biologic Y, I will
also examine a technology that can replace these batch reactors. More specifically, I will look at
how tubular reactors can be used, and what their potential advantages and disadvantages are.
There is a collaboration between Sandoz Biopharmaceuticals and Professor Rainer Hahn from
the University of Natural Resources and Life Sciences in Vienna. This is part of the ongoing
partnership between industry and academia called the Austrian Center of Industrial
Biotechnology (ACIB). My thesis will not provide details regarding the mathematical modeling
of such reactors, as I am primarily concerned with the financial impact of this technology.
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Furthermore, the savings realized in my models will stem from the chromatography
technologies, as will be described in Chapter 5.
Currently, several of Biologic Y's downstream purification steps involve the mixing of
reactants in large tank reactors. The reactants are mixed under specific conditions, and after a
pre-determined amount of time, the reaction is assumed to have run its course, and then the
processed protein product is moved on to the next step. These reaction steps are fairly reliable,
as they have been perfected over many years of experience. However, this is a batch reaction,
and does not permit for a fully continuous downstream process.
With tubular reactors, the reactants are continuously fed into a tube-shaped reactor. They
combine to form a reaction solution that flows through a pre-determined length of pipe. As the
reactants flow through this pipe, they react, just as they do in the tank reactor. Finally, at the end
of the tubing, the reactants have completely reacted to form the desired product. As the reactor
is being continuously fed with input streams, it is also continuously releasing product in its
output stream (see Figure 10).
ContinuousIy
fed input
Continuously
output
Figure 10. Tubular reactor with continuous input and output
The length of tube that is required for the reaction to be completed depends on the
residence time required for the reaction. This may or may not be less than what is required for a
batch reactor. There may be instances where the residence time required is decreased because
the reactants are in much closer proximity, and can react faster. Similarly, if the heat or pH of
the solution needs to be changed, this may be accomplished in a much shorter time frame, as the
cross sectional area of the tubing will be much smaller than that of a tank reactor (see Figure
11). However, if the reaction is a re-folding reaction, which does not depend on the proximity of
reactants, then this time requirement may not be different.
vnso
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Figure 11. Advantage of tubular reactor - decreased cross sectional area
To calculate the amount of tubing required for a particular reaction, we need to know the
residence time required (to be determined empirically with the particular tube specifications), the
tube diameter (this can be given by the type of tubing available), and the flow rate (this is
determined by the overall rate determining step of the process). Then, as per discussions with
Professor Rainer, we need to make sure that the fluid flow is laminar by ensuring that the
Reynolds number is less than 2,300. Turbulent flow can expose the proteins to undue stress and
strain. For example, the following hypothetical case will illustrate how to determine the length
of tubing:
* Inflow rate of protein solution = 5 L/min
* Inflow rate of reactant = 5 L/min
* Total flow rate = 10 L/min
e Residence time required = 60 min (pre-determined based on tube diameter)
* Volume of tubular reactor = 10 L/min * 60 min = 600L = 600,000 mL
e Tube diameter = 4 cm
" Tube area = 4*71 cm2
" Tube length = 600,000 mL/47E cm 2 = 47,771 cm = 478 m
Now, to calculate the Reynolds number, one just needs to use the fluid's density and
viscosity, as well as the tube diameter and the linear flow rate:
Reynolds number = Re = pvD
kg (im
where p = density (-z),v = f low velocity ,
mse
D = diameter(m), and y = viscosity ( kg )
m * sec
Finally, another advantage of tubular reactors is that mixers can easily be installed
throughout the tubing, accelerating the reaction even more.
3.4 Spray-drying
The last step of the downstream purification of Biologic Y is the freeze drying, or
lyophilization process. This is a rather complex, time-consuming, and expensive process
(described in the previous chapter). Spray-drying offers an alternative method of achieving the
same goal of removing the liquid content to create a powdery protein product.28 The basic mode
of action is that the solution is rapidly sprayed out of a nozzle. The nozzle utilizes atomizers to
disperse the product containing fluid into very small droplets. A hot drying gas is then applied
either co-currently or counter-currently, causing the fluid from these droplets to evaporate. As
the liquid evaporates, small particles of protein product, with minimal moisture, are deposited
within the drum of the spray-dryer, while the hot gas containing the evaporated fluid is quickly
removed. This can be complicated with protein mixtures, as they are often heat sensitive, and
can degrade quickly. Sandoz has had limited success using spray-drying with other biologics, as
the yields have been lower than those achieved with lyophilization. However, after discussing
this technology with Professor Gerhard Winter at the Ludwig Maximilian University in Munich,
I believe this process can still be viable with biologics.
A thorough investigation of the application of spray-drying to biologics is beyond the
scope of this thesis. It is a very complicated process, and deserves an independent investigation.
Adam Youngman, LGO 2009, wrote a thesis on the economics of spray-drying with small
molecules, and this can be used as a reference.29 However, the stability of biologics makes the
application of this technology particularly challenging.
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4 Process Data and Model for Biologic X
4.1 Sources of data
I was able to supplement my literature review with a tour of this facility, as well as in-
depth discussions with the scientists and engineers involved in this effort. After familiarizing
myself with the overall downstream purification process, I determined that there were certain
parameters and data that would be required for my model:
" Yield of each step
e Time spent in each step
e Cost of raw materials
" Cost of overhead for running the line that will produce Biologic X
For the first two items listed, I was able to obtain the required information from Dr.
Richard Hoelzl, who runs the line that currently produces Biologic X. For the last two items,
Angela Gruber, who also works in the Schafetnau plant (finance department), was able to help
me obtain the necessary data. This data will not be disclosed in this thesis - I will use fictitious
numbers; however, the results should convey the same basic message as my real data.
4.2 Model of current batch chromatography processes
4.2.1 Assumptions
After I collected the data, I determined which were the most accurate and representative
campaigns (with the help of my supervisor and Richard Hoelzl), and then averaged the data from
those runs. This gave me the following data that would be used in my model:
e Volume and yield of product in the upstream process
e Yield at each downstream process step
* Overall yield of downstream processes
Thus, for the model that I submitted to the company, I assumed that the average of the
last several campaigns could accurately predict the product yields in future runs. However, as
more data is collected, and the runs become more efficient, the company must update the model.
4.2.1.1 Yield data
Yield data is an important metric in my model, as it determines how much product will
be left at the end of one process, and available for the next step. The basic equation for my
model is as follows:
e Step i: input1(grams per batch) x yieldi = output i(grams per batch)
e inputi+1 = outputi
e Step i + 1: inputi, 1 x yieldi,1 = outputi,1
By combining all of this data, we could determine the overall yield of the process. This
is simply: process input from upstream process x (HB 1 yieldi) = overall yield.
Thus, by using data from the previous runs, we can predict what product output we could
expect with a given input. Similarly, we can also predict that changing the yield of a specific
step can change the overall yield. This has two implications:
* If the yield of a step has increased, then all downstream steps will now process more
product - this will result in increased consumption of raw material. My model
assumes that the percentage yield of these downstream steps will remain constant.
o For example (data all fictitious), if we had the following step yields:
Step 1 60%
Step 2 60%
Step 3 60%
o The overall yield of these processes would be: 60% x 60% x 60% = 21.6%
o Now, if the yield of step 2 were changed to 90%, our system will look like the
following:
Step 1 60%
Step 2 90%
Step 3 60%
o Now, the overall yield will be: 60% x 90% x 60% = 32.4%
* The cost of the product should decrease as the yield increases. This is because much
of the fixed costs (overhead, labor, maintenance) can now be spread over more
product.
o For example, if we have the following data for a batch:
Total COGS for downstream $1000
processes
Product achieved 50 grams
o From this data, we see that the COGS associated with the downstream
purification is: $1000/50g=$20 per gram of product.
o Now, if the yield is increased from 21.6% to 32.4%, we get the following
data:
Total COGS for downstream $1000
processes
Additional COGS from increased raw $100
material required
Product achieved 32.4%
50 grams x = 75 grams
21.6%
o From this data, we see that the COGS associated with the downstream
purification is: $1100/75g=$14.67 per gram of product, a decrease of 26.7%.
4.2.1.2 Resin utilization and cost
Chromatography resins lose their ability to bind proteins after they have been used and
washed multiple times. After a column of resin is used for a separation process, it must be
cleaned, equilibrated, and prepared for the next round. This process of binding, eluting,
cleaning, and equilibrating has a "wear and tear" effect on the resin beads. The longevity of the
resin depends on many factors:
" The type of resin
e The type of buffers used for eluting, cleaning, equilibrating
e Other conditions, such as salt concentrations and pH
For this reason, the lifetime of the resin needs to be determined for the specific
circumstances of each process. This is determined empirically, and usually described in terms of
cycle life. So, a cycle life of 100 means that the resin can be used for 100 cycles or runs before it
should be replaced. To determine the resin cost for each cycle, the following calculation is
performed:
Resin cost $1000/L
Resin cycle life 100
Resin volume for this process 1 OOL
. To calculate the resin cost/cycle: $100 x 100L resin x resin $1000
L 100 cycles cycle
This is an important cost to consider, as resins can be quite expensive, especially those
containing Protein A.
4.2.1.3 Buffer consumption
In addition to expensive resins, a significant number of buffers are utilized during a
purification process. They are used in the following ways:
* To transport the protein of interest
* To elute the protein off of the resin
* To transport other reactants/catalysts
* To wash and equilibrate the resins
The actual volume of buffer required for this step is often determined by the volume of
the column. Typically, buffer requirements are often described as number of columns of solution
required for each step. For example, if a column volume is 1 OOL, and there are 5x column
volumes of buffer A required for a certain step, then the total volume required is 500L. These
numbers can become quite large, and if the buffer is expensive, the costs can be significant.
4.2.2 Current batch chromatography model
For the current batch process, I will use the following data (fictitious):
Upstream fermentation batch volume 10,OOOL
Titer 2mg/L
Product/batch 20g/batch
I will model the process such that there are three chromatography columns, one
enzymatic reaction, and two filtration steps. The following diagram (Figure 12, fictitious)
illustrates the flow of the protein product.
Upstream processes
Downstream processes
Ia 10,000-L, 2 mg/L
j~rcs. -
DRUG SUBSTANCE
Figure 12. Biologic X batch process model
The following data (fictitious) characterize the downstream processes - both product
yields and costs.
Filter 1 Chrom. 1 Chrom. 2 Enz. Rxn. Chrom. 3 Filter 2
Yield 95% 90% 90% 90% 70% 90%
Binding 20g/L 20g/L 1Og/L
capacity of
resin
Cost of $1000 $1000 $1000
Resin/L
Resin cycle 100 100 100
life
Cost of $10,000 $10,000
filter (one
time use)
Cost of $100 $100 $500 $100
buffer or
reagent
per cycle
2
I Filtration 1
Enzymatic
Reaction
Filtratior
Using this data, we can model our process to determine the overall yield and cost per
batch (see Figure 13). I use the following calculations:
" For the filters:
o Input = output from previous step
o Output = input*yield
o Cost = cost of filter
" For the chromatography steps:
o Input = output from previous step
o Output = input*yield
o Cost = resin cost (per cycle) + buffer cost
input (g) $ 1
* resin cost = i catci) x cost of resin (-) xbinding capacity ()L cycle life
* buffer cost =
cost of buffer as listed x volume of buffer per cycle (L)
" For the enzymatic reaction:
o Input = output from previous step
o Output = input*yield
o Cost = cost of buffer/reagent as listed above
* For the overall reaction:
o Overall yield = Hl individual yields
o Total product = input*overall yield
o Total cost (downstream purification)/batch = E individual costs = $52,401
measured
calculated
Upstream fermentation Filter 1 Chromatography 1 Chromatography 2
Volume (L): 10,000 Input (g): Input (g): Input (g):
Titer (g/L): 2 Yield: 95% Yield: 90% Yield: 90%
Product (g): Output (g): Output (g): Output (g):
Cost: $ 10,000 Cost: Cost:
Enzyme Reaction Chromatography 3 - MCSGP Filter 2
Input (g): Input (g): Input (g): Drug Substance
: 90% YieYield: 90% Overall yield:
Output (g): Output (g): Output (g): Total product:
Cost: $ 500 Cost: Cost: 0,000 Total Cost:
Figure 13. Yields and costs for the downstream processes of Biologic X
These costs reflect the variable costs associated with a batch. In addition, fixed costs
must be spread over the many batches that are made over a certain time period. This includes
overhead, maintenance, and labor. In the case of Biologic X, we have this data (fictitious).
Fixed cost per year $10,000,000
Number of batches per year 40
Fixed cost/batch $250,000/batch
So, when the variable costs are added to the fixed costs, the total cost of downstream
purification for one batch is: $250,000+$52,401 = $302,401. This translates into a cost of
$302,401/8,726g = $34.65/gram of drug substance.
4.3 Model with MCSGP system included
4.3.1 Assumptions
In this hypothetical model, we will assume that we will replace the lowest yield
chromatography step with the MCSGP process. This is because we want to generate the most
savings as possible, and this is only possible when the initial yield is low. For example, with the
current batch process in the third chromatography step we can realize the following yield
increase with MCSGP:
Loss of product with current batch process 30%
Factor decrease in loss of product from the 1.75x-3.5x30
literature
Factor decrease used in this thesis 1.75x
(conservative estimate)
New loss of product with MCSGP process 30%/1.75 = 17.14%
New effective yield with MCSGP 100% - 17.14% = 82.86%
When determining the factor decrease in lost product with the MCSGP process, I used
the lower end of the range I obtained from the literature and the company. Thus, by dividing the
lost product by 1.75, I was conservatively estimating the decrease in lost product with this new
process. Specific numbers for Biologic X are not available, and there are no good mathematical
models that can predict this result. The only way to determine the true effective yield increase is
to perform an experiment with Biologic X and the specific resin to be used. Now, the overall
yield for the process is increased (see Figure 14).
measured
calculated
Chromatography 2
Input (g):
Yield: 90%
Output (g):
Cost:
Filter 2
Input (g): Drug Subs
Yield: 90% Overall yield:
Output (g): $0;Total product:
Cost: $ 0000 Total Cost:
Figure 14. Yields and costs for the downstream processes of Biologic X with MCSGP
In addition, with MCSGP there are potential decreases in buffer utilization. For part one
of this thesis, I will ignore this savings, as it turns out to be insignificant compared to the cost
savings generated from the increased yield.
4.3.2 Results
Now, we can calculate the new cost per gram of drug substance. The variable costs have
stayed the same, as have the fixed costs (we assume the process takes the same amount of time
and utilizes the same amount of overhead). Also, because the only step after the third
chromatography step is a filter step, there are no increased raw materials utilized during this
purification stage. However, if the first chromatography step were replaced by an MCSGP, the
increased yield would cause an increase in inputs into the subsequent steps, forcing them to
utilize more raw materials (resin, buffers). This will be shown in the second part of the thesis.
So, the cost per batch remains $302,401, with an output of 10,329 grams of product. Thus, the
cost is $302,401/10,329g = $29.28/gram of drug substance. This results in a ($34.65-
$29.28)/$34.65 = 15.5% decrease in COGSfor the drug substance.
Note that this number can be significantly larger with the following conditions:
e If the yield for the step was initially lower (for example, if the initial yield was 40%, the
increased effective yield would be 66%, an increase of 26% vs. 13% used in this
example)
e If the fixed costs represented a larger portion of the total costs
e If we included the decreased buffer requirements
In fact, with Biologic X, we were able to predict a significantly higher cost savings
when we modeled one of its chromatography steps with the MCSGP technology (the lowest
yield step).
4.4 Financial Analysis
With the data obtained from the previous section, namely the change in the COGS of the
drug substance, we can determine the change of the estimated NPV of the projected sales of
Biologic X. Initially, I created a forecast model, which included my own estimates of
penetration and market size. However, it turned out that Sandoz had a much more sophisticated
model that included sales in various indications, as well as different dosage forms. Within this
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model, there was an input for the cost of the drug substance, which then directly affected the
NPV estimate. I decided to use this model instead of the one I developed because it was more
accurate, and it included much more information than what I was privy to. I used the data I
obtained from the models described previously to obtain the potential savings from using the
MCSGP technology:
e eNPVbatch =
expected NPV with Sandoz forecast model with cost of drug substancebatch
* eNPVMCSGP =
expected NPV with Sandoz forecast model with cost of drug substanceMCSGP
e potential savings = eNPVMCSGP - eNPVbatch
With the result obtained from the data from Sandoz, I was able to show a significant
amount of savings with the MCSGP. However, I had to determine whether the benefit of
developing this technology would outweigh the developmental risks and costs associated with
novel technology (it is still in lab scale only). At this point, the next step would be to do a small
experiment with Biologic X to determine if predicted yield increases can be realized. This will
give Sandoz the additional knowledge required to decide whether or not to proceed with this
technology. The experiment is expected to cost around $1OOK-$150K, but will add a lot of
information about this particular system. The question I needed to address was whether it is
worth doing this experiment, given all the uncertainties. To do this, I utilized a decision tree
analysis, where I used the following inputs:
* The estimated "effective yield" increase (this is actually a factor by which the lost
product is decreased by - see section 4.3.1, Assumptions)
* The NPV of developing a commercially scaled MCSGP process
* The % probability that the MCSGP works
* The sensitivity (ability to detect a positive result) of an initial experiment
* The specificity (ability to know if the MCSGP does not work) of an initial experiment
The calculations for this decision tree are as follows (see Figure 15 for diagram), using
the following hypothetical data:
Estimated effective yield increase 1.75 (as per before)
NPV of development of MCSGP process -$5,000,000 (an investment)
NPV of Biologic X with all batch processes $80,000,000
(baseline)
NPV of Biologic X with MCSGP process at $100,000,000
third chromatographic step
% probability that MCSGP works with 30%
Biologic X
Sensitivity of experiment 60%
Specificity of experiment 80%
Initially, the decision is made whether to perform the experiment:
a. If Sandoz performs the experiment, there is a 30% chance that the MCSGP works
and a 70% chance it does not work.
i. If it does work, there is a 60% chance that this experiment will show this
convincingly (that is, the experiment will show a significant yield
increase) - this translates into an overall probability of 30%*60% = 18%.
1. The payoff in this scenario is the NPV with the MCSGP
($100,000,000) plus the NPV of the investment (-$5,000,000)
$95,000,000.
ii. If it does work, there is a 40% chance that the experiment will fail to show
this - this translates into a 30%*40%= 12% probability.
1. The payoff in this scenario is just the baseline NPV of
$80,000,000, as the company does not invest in developing the
MCSGP technology further.
iii. If it does not work, there is a 100%-80% = 20% of a false positive - that
the experiment will detect a significant improvement, when in fact future
scale-up of the equipment will not provide the same result; this translates
into an overall probability of 70%*20% = 14%.
1. The payoff in this scenario is the baseline NPV of $80,000,000 (as
the MCSGP process in this case does not provide significant
benefits) minus the developmental cost of -$5,000,000 (because in
this situation, Sandoz develops the MCSGP thinking that it would
be very helpful) for a total of $75,000,000.
iv. If it does not work, there is a 70%*80% = 56% chance of the experiment
confirming this result.
1. The payoff in this scenario is just the baseline of $80,000,000, as
Sandoz does not invest in this technology.
b. If Sandoz does not perform the experiment, the NPV is the baseline, as shown in
the above table.
estimated yield increase (1=baseline) 1.75
NPV of commercial scale investment in $M -$5,000,000
eNPV baseline
eNPV with MCSGP savings
% chance of MCSGP working 30%
sensitiity of experiment 60/6
specificity of expedment 80%
NPV Biologic X Investment Total DS cost
' ht ed average=
basline
Savings
Figure 15. Weighted average of different payoffs with Biologic X
We see that with these hypothetical numbers the NPV of the potential savings is greater
than the cost of the initial investment on the experiment, which would warrant an investment in
this technology. This is indeed what happened when I used the data from Biologic X - this
showed a positive NPV, and so the company has decided to move forward and perform future
experiments.
4.5 Monte Carlo Simulations
The discussion from the previous section focused on a single set of assumptions.
However, Sandoz must consider alternative situations, which may be better or worse than the
baseline conservative estimates that I made. What if the "effective yield" increase was only
1.5x, or 3x? What if there is actually a 50% chance that the MCSGP works? By changing these
factors, our results can change dramatically. To study this phenomenon, I performed some
Monte Carlo analyses with the following scenarios:
Worst case Base case Best case
Yield increase - eNPV of Biologic X 1.2x(minimal), 1.75x(baseline), 3x(max), which
which translates which translates translates into
into eNPV of into eNPV of eNPV of
$85,000,000 $100,000,000 $150,000,000
NPV of commercial scale investment, -$5,000,000
standard deviation = $1,000,000
% chance of MCSGP working, 30%
standard deviation = 10%
Sensitivity of experiment, standard 60%
deviation = 10%
Specificity of experiment, standard 80%
deviation = 10%
More specifically, I used Excel plug-in Crystal Ball to perform the simulations. I used a
triangular distribution for the eNPV of Biologic X, and normal distributions for the other
parameters (see above chart for exact numbers). These are all fabricated numbers, and one must
carefully determine the limits to these parameters, as well as the likely distributions. The
simulation yielded the following frequency chart (see Figure 16) after 5,000 runs:
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Figure 16. Monte Carlo simulation
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The summary statistics are shown in Figure 17. They show that at the base case, as we
expected, the savings from this technology is $2,000,000. This result justifies an initial
investment into this technology, which will be significantly less than these forecasted savings. In
addition, there is only a 5.05% chance of a negative NPV, clearly indicating there is much more
upside with this technology.
Statistic Forecast values
Trials $5,000
Base Case $2,000,000
Mean $4,068,289
Median $3,323,699
Standard Deviation $3,337,116
Variance $11,136,344,681,960
Skewness 1.13
Kurtosis 4.82
Coeff. of Variability 0.8203
Minimum ($2,172,897)
Maximum $29,267,649
Mean Std. Error $47,194
Figure 17. Summary statistics for simulation
Finally, the simulation shows that the savings derived from this technology is most
sensitive to the yield increases provided by the MCSGP process (Figure 18). This makes sense,
as I have shown how much yield increase can affect the potential savings.
-200
-10
-160
-140
-120
-100
40
20
0
u-s I
.OW Took 4,925 Dimpiwied
Figure 18. Sensitivity analysis
There are other factors that need to be considered with this project. There are regulatory
hurdles and costs associated with implementing this system, which I have not included. There is
the added benefit of potentially using the know-how obtained during this project for other
biologics in development. In fact, currently, there are processes which have low-yield
chromatography steps that could potentially benefit greatly from the MCSGP technology. Thus,
there are many other pros and cons that need to be factored in; however, my initial assessment
shows that it is financially advisable to take the next step forward - a laboratory-scale
experiment with Biologic X.
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CHAPTER 5
PROCESS DATA AND MODEL FOR BIOLOGIC Y
5 Process Data and Model for Biologic Y
5.1 Sources of data
I was able to supplement my literature review with a tour of this facility, as well as in-
depth discussions with the scientists and engineers involved in this effort. The data that I
obtained in this part of the project were very similar to that from the first part:
" Yield of each step
e Time spent in each step
" Cost of raw materials
" Cost of overhead for running the line that will produce Biologic Y
I was able to obtain the engineering and scientific data from Dr. Martin Ludwicek, Dr.
Norbert Palma, and Dr. Bernhard Widner, and financial information from Dr. Valentin Resinger,
Dr. Johannes Reiter, and Martina Messner.
5.2 Model of current batch chromatography processes
5.2.1 Assumptions
Similar to the first part of this project, after I collected the data, I determined which were
the most accurate and representative campaigns (with the help of my supervisor and Martin
Ludwicek), and then averaged the data from those runs. This gave me the following data that
would be used in my model:
" Volume and yield of product in upstream process
" Yield at each downstream process step
" Overall yield of downstream processes
Thus, for the model that I submitted to the company, I assumed that the average of the
last several campaigns could accurately predict the product yields in future runs. However, as
more data is collected, and the runs become more efficient, the company must update the model.
The purification process for Biologic Y is more complicated than that of Biologic X.
5.2.1.1 Yield data
The yield data is treated in a manner similar to the first part of this project (see Section
4.2.1.1 for more details).
5.2.1.2 Resin utilization and cost
My treatment of resin costs are similar to that from the previous chapter (see 4.2.1.2). In
addition, as I will be using the BioSC process in the model, my resin utilization in these
instances will change. I was able to obtain data from the company (Novasep) regarding the
increased resin utilization they were able to achieve with similar biologics - this ranged from
85% to 140%. For my calculations, I used a conservative estimate of 75%. Thus, if as in the
previous section, the first chromatography step had a resin utilization of 20 g/L, the predicted
utilization with the BioSC process would be:
" new resin utilization = batch resin utilization * 1.75(f actor increase)
e new resin utilization = 20g * 1.75 =
L L
5.2.1.3 Buffer consumption
The treatment of buffer consumption in this section is very similar to that in the previous
section, except now I will incorporate the potential savings associated with decreased buffer
consumption. This is because several chromatography columns will have high initial yields, so
applying the MCSGP process will not impart the significant cost savings associated with yield
increases that were observed with Biologic X. As such, the savings from decreased buffer
consumption will become more significant.
With both the MCSGP3' and BioSC32 processes, buffer consumptions can be decreased
significantly (as discussed with company representatives). For my calculations with these two
technologies, I used a conservative estimate of 40% as the decrease in buffer requirements. So,
for the first chromatography step, if 3L of buffer A is typically required for the batch process,
then we would expect the following:
" New buffer requirement = old buffer requirement * (1 - factor decrease)
e New buffer requirement = 3L * (1 - 40%) = 1.8L
5.2.2 Current batch chromatography model
For the current batch process, I will use the same upstream data as the previous model:
Upstream fermentation batch volume 10,000L
Titer 2mg/L
Product/batch 20g/batch
I will model the process such that there are three chromatography columns, and one
enzymatic reaction. I will not include the lyophilization step, which will be discussed later. The
following diagram (Figure 19, fictitious) illustrates the flow of the protein product.
I pee10,0000L, 2 mg/L
Upstream processes p
Downstream processes
DRUG SUBSTANCE
Figure 19. Biologic Y process model
The following data (fictitious) characterize the downstream processes - both product
yields and costs. To make matters simple, I will assume that each chromatography step requires
only one buffer (though in reality, they require many for the different steps - cleaning, pre-
equilibrating, equilibrating). In addition, I assumed that for the enzymatic reaction, the buffer
and reagent required are dependent on the amount of protein product from the previous step
(grams output from chromatography step 1).
Chrom. 1 Enz. Rxn. Chrom. 2 Chrom. 3
Yield 90% 95% 50% 90%
Binding capacity of resin 1 Og/L 20g/L 20g/L
Cost of resin/L $5,000 $1,000 $1,000
Resin cycle life 100 100 100
Buffer + reagent required for 0.05
enzymatic reaction (L/gram of
protein product)
Cost of buffer + reagent required $2/L
for enzymatic reaction ($/L)
Buffer volume for 1 Ox 5x 5x
chromatography step (in column
volumes)
Buffer cost/L $5/L $1/L $1/L
In addition to the calculations made in the previous chapter, I determined the following
values (see Figure 20 for flow sheet):
* Column volume - this will be important to determine the amount of buffer required for
this step: column volume = input into chromatography column (g)binding capacity of resin (!)
* Buffer required for chromatography step: buffer volume = column volume(L) *
buffer volume per column
" Buffer/reagent volume needed for the enzymatic reaction - depends on the input from the
previous step: buffer + reagent volume = output from previous step (g) *
volume required per gram protein (k)
e Buffer costs: costs = buffer vol. required(L) x buffer cost( )
measured
calculated
Upstream fermentation
Volume (L):
Titer (g/L):
Product (g):
Chromatography 1
Input (g):
Yield:
Output (g):
Column vol. (L):
Resin costs:
Buffer required (L):
Buffer costs:
Input (g):
Yield:
Output (g):
Column vol. (L):
Buffer costs:
Chromatography 2 Chromatography 3
Input (g):
Yield: 50%
Output (g):
Column vol. (L):
Resin costs:
Buffer required (L):
Buffer costs:
Input (g):
Yield: 90%
Output (g):
Column vol. (L):
Resin costs:
Buffer required (L):
Buffer costs:
Drug Subs
Overall yield:
Total product:
Total cost:
Figure 20. Yields and costs for the downstream processes of Biologic Y
We see that the total cost per batch is $221,038, to which I will now add the fixed costs (I
will use the same fictitious data as I did with Biologic X).
Fixed cost per year $10,000,000
Number of batches per year 40
Fixed cost/batch $250,000/batch
So, when we add the variable costs with the fixed costs, we determine that the total costs
of downstream purification for one batch is: $250,000+$221,038 = $471,038. This translates
into a cost of $471,038/7,695g = $61.21/gram of drug substance.
5.3 Continuous Model
For the second part of my internship, I modeled the purification process of Biologic Y as
continuous. To do this, I did the following (see Figure 21):
Enzymatic Reaction
95%'10,0002
* For each of the chromatography steps, there are three potential options: the traditional
batch process, the MCSGP process, and the BioSC process. The implications of each one
will be discussed in the following subsections.
* For the enzymatic reaction, I did not assume any savings from potential decreased time,
space, or labor requirements. This is because the key parameters still need to be
determined. For example, with specific enzymatic reactions, it is unclear whether using a
tubular reactor will decrease the time requirements. Similarly, it is unclear whether the
tubing will be more expensive, or require less space. It will, however, allow for
continuous processing, so it is important to consider. The only influence on the costs of
this step will be the amount of output from the previous step, as it will change the amount
of buffer/reactant required.
In the following subsections, I will break down the cost changes as I implement different
technologies into the model.
Upstream processes
Downstream processes
10,OOOL 2mg/L
vs.
Lyophilization
and then drug
substance
Bio-SC Enzymatic rxn. Bio-SC Bio-SC
Figure 21. Biologic Y continuous process model
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5.3.1 Resin and Buffer Costs
To illustrate the potential savings with resin costs, I will use the first chromatography
step as an example. However, this should be applied to all of the steps.
e If the chromatography step is in batch mode, the following values apply (Figure 22,
taken from Figure 20):
Chromatography 1
Mode: Batch
Input (g):
Yield: 90%
Output (g):
Column vol. (L):
Resin costs:
Buffer required (L):
Buffer costs:
Figure 22. Chromatography step 1 if batch
e If we change the mode to MCSGP, then we need to account for other factors, such as
increased yield and buffer costs:
o For resin, we assume that the amount of lost product goes down by a factor of
1.75, increasing the "effective yield" - see section 4.3.1 for the necessary
calculations. We add another cell in the model to account for this increase in
yield, which then causes the actual yield and output to increase (Figure 23).
Chromatography 1
Mode: Batch
Input (g):
Yield: 90%
Increase in yield: 1.75
Final yield:
Output (g):
Column vol. (L):
Resin costs:
Buffer required (L):
Buffer costs:
Figure 23. MCSGP model with increased yield
o However, we also have to consider the decrease in buffer requirements, and their
subsequent cost savings (as per above, decreases by 40%). As the buffer
requirements assumed in this model are the same for the MCSGP and BioSC
process, these changes are applied when either of these models is chosen. The
following figure shows the first chromatography step as completely modeled to
reflect the potential financial impact of the MCSGP process - the yield increase
and the decrease in buffer costs.
Chromatography 1
Mode: MCSGP
Input (g): M
Yield (if batch): 90%
Increase in yield if
MCSGP: 1.75
Final yield:
Output (g):
Resin utiliz. if batch
(g/L): 10
Increased utiliz. if
BioSC: 1.75
Actual resin utiliz.
(g/L):
Column vol. (L):
Resin costs:
Buffer required if
batch (L):
Decreased buffer
requirement if
MCSGP or BioSC: 40%
Actual buffer
required (L):
Buffer costs:
Figure 24. Chromatography step 1 completely modeled as MCSGP
* If we change the mode to BioSC, then we need to consider an additional factor - the
increased resin utilization:
o For resin, we assume that the resin utilization increases by a factor 1.75 (as
above). This needs to be added to our model. This decreases the size of the
column, effectively decreasing the amount of resin required from 2,000L to
1,143L:
column volume =
input of product (g) 20,000g
binding capacity * factor increase for BioSC 10 * 1.75
= 1,143L
o In addition, the BioSC has the added benefit of decreased buffer requirements, as
described in the MCSGP section. The chromatography column, when modeled as
a BioSC process has the following attributes (see Figure 25). Note that the yield
remains the same as when it is a batch reactor.
Chromatography 1
Mode:
Input (g):
Yield (if batch):
Increase in yield if
MCSGP:
Final yield:
Output (g):
Resin utiliz. if batch
(g/L):
Increased utiliz. if
BioSC:
Actual resin utiliz.
(g/L):
Column vol. (L):
Resin costs:
Buffer required if
batch (L):
Decreased buffer
requirement if
MCSGP or BioSC:
Actual buffer
required (L):
Buffer costs:
Figure 25. Chromatography step
BioSC
90%
1.75
10
1.75
40%
1 modeled as BioSC process
o Comparing the three different options, with all of the new features included in the
model, we see the benefits of both the MCSGP and the BioSC (see Figure 26).
However, there are some benefits that have not yet been considered:
- Decreased space requirements associated with the decreased buffer
requirements
- Implications of the increased yield associated with the MCSGP.
ChmMOgMPhy 1
Mode: eath
Input (g):
Yield (if batch):
Increase in yield if
MCSGP-
Final yield:
Output (g):
Resin utiliz. if batch
(g/O:
Increased utiliz. if
BioSC:
Actual resin UtiliL
(g/L):
Column vol. (L):
Resin costs:
Buffer required if
batch (L):
Decreased buffer
requirement if
MCSGP or BicSC:
Actual buffer
required (L:
Buffercosts:
90%
1.75
10
175 VS.
Choaetgrphy1
Mode: MCSGP
Input (g):
Yield (if batch):
Increase in yield if
MCSGP-
Final yield:
Output (g):
Resin utiliz. if batch
(g/O:
Increased utiliz. if
BioSC:
Actual resin utiliL
(g/.):
Column vol. (Q:
Resin costs:
Buffer required if
batch (Q:
Decreased buffer
requirementif
MCSGP or BioSC-
Actual buffer
required (Q:
Buffercosts:
90%
1 -A
10
1 7r
VS.
Input (g):
Yield (if batch):
Increase in yield if
MCSGP-
Final yield:
Output(g):
Resin utiliz. if batch
(g/O:
Increased utiliz. if
BioSC:
Actual resin utiliz.
(g/Q :
Column vol. (Q:
Resin csts:
Buffer required if
batch (L:
Decreased buffer
requirement if
MCSGP or BioSC-
Actual buffer
required (Q:
Buffercss
Figure 26. Comparison of the three potential models
o When we apply this model to all of the three chromatography steps, we get the
following combined model (Figure 27):
Ch ography1
Mode: .osC
90%
1.75
10
175
40%
measured
calculated
Chromatography 1
Mode: MCSGPUpstream fermentation
Volume (L): 10,000
Titer (g/L): 2
Product (g):
Input (g):
Yield (if batch):
Increase in yield if
MCSGP:
Final yield:
Output (g):
Resin utiliz. if batch
(g/L):
Increased utiliz. if
BioSC:
Actual resin utiliz.
(g/L):
Column vol. (L):
Resin costs:
Buffer required if
batch (L):
Decreased buffer
requirement if
MCSGP or BioSC:
Actual buffer
required (L):
Buffer costs:
90%
1.75
Enzymatic Reaction
Input (g):
Yield: 95%
Output (g):
Buffer vol. req. (L):
Buffer costs:
10
1 7r
40%
Chromatography 2
Mode Batch
Input (g):
Yield (if batch):
Increase in yield:
Final yield:
Output (g):
Resin utiliz. if batch
(g/L):
Increased utiliz. if
BioSC:
Actual resin utiliz.
(g/L):
Column vol. (L):
Resin costs:
Buffer required if
batch (L):
Decreased buffer
requirement if
MCSGP or BioSC:
Actual buffer
required (L):
Buffer costs:
20
40%
Chromatography 3
Mode Batch
Input (g):
Yield (if batch):
Increase in yield:
Final yield:
Output (g):
Resin utiliz. if batch
(g/L):
Increased utiliz. if
BioSC:
Actual resin utiliz.
(g/L):
Column vol. (L):
Resin costs:
Buffer required if
batch (L):
Decreased buffer
requirement if
MCSGP or BioSC:
Actual buffer
required (L):
Buffer costs:
Drug Subs
Overall yield:
Total product:
Total cost:
20
1 7;
Figure 27. Downstream purification process for Biologic Y
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5.3.2 Inventory Holding Costs
With the proposed continuous technologies, we expect decreased resin and buffer
requirements. For the former, the increased yield offered by the MCSGP process, and the
increased resin utilization offered by the BioSC process could significantly decrease the amount
of resin the company needs to hold during the year. Similarly, for the latter, the MCSGP and
BioSC processes will also use less buffer. Unfortunately, when I discussed the issue of
inventory holding costs with the finance department, this was not a metric they considered in
their calculations. However, given the decreased holding requirements associated with this
technology, I will include this calculation, as it should be considered. I conservatively used an
inventory holding cost of 20%, even though most industries use higher numbers such as 25%.33
Regarding resin, after talking with the engineers in the plant, I made the assumption that
the company will always have a volume of resin in inventory in the case that the currently used
resin is damaged and needs to be replaced quickly. For example, in the case above, 2000L of
resin is required for the first chromatography step, so there will be 2000L of that same resin in
inventory. Because the resin costs $5000/L, the annual inventory holding cost will be:
inventory holding cost = $5,000 per L * 2000L * 20% = $2,000,000.
Regarding the buffer, I assumed after talking with the engineers that the plant would hold
4x the amount of buffer required for one batch - this number is likely higher. In this case, then,
the inventory holding for the buffer used in the first chromatography step is:
inventory holding cost =
column volume * buffer volume required * buffer cost per L * inventory holding =
2000L * 10x * $5 per L * 20% = $8,000 per year.
5.3.3 Space Costs
To determine the costs associated with the decreased buffer requirements if one or more
of the chromatography steps are modeled as continuous, we must first determine how much
buffer storage space costs. To do this, I obtained the reinvestment cost of the plant in Kundl that
was producing Biologic Y - $50M (fictitious). I was then able to find the total surface area of
the plant, and the surface area dedicated to reactors: 6,000 m2 and 4,000 m 2, respectively. I then
assumed that the cost per square meter of buffer storage tanks was somewhere between the per
area cost of reactor space and the whole space (which includes walkways and other less
productive areas). I then used the surface area (500m 2 ) dedicated to buffer storage tank to
determine the total cost of space dedicated to buffer tanks:
Reinvestment cost of Biologic Y plant $50,000,000
Surface area, total and just for reactors 6,000 m2 and 4,000 m2
Cost per M2 , total and reactor $8,333/m2 , and $12,500/m 2
Average cost per m2 for buffer storage area $10,417/m2
Space dedicated to buffer storage 500m 2
Cost of buffer storage space 500m 2*$1 0,417/m 2=$5,208,333
Now, to determine the cost savings associated with the different continuous technologies,
I took a baseline calculation of the total buffer required (from all steps) when all of the
chromatography steps are set in the batch mode. This is the situation where the cost of the buffer
space is $5,208,333. Then, when specific steps are switched to continuous, the amount of total
buffer required is then decreased. I took the ratio of this new buffer requirement to the baseline,
and then multiplied by the baseline cost. This is a rough estimate of the amount of capital that
could potentially be saved if those specific steps are continuous.
Total buffer required (baseline) 60,900 L
Total buffer required when all steps are 36,943 L
MCSGP
Expected cost of buffer storage space (36,943 L/60,900 L) * $5,208,333 = $3,159,453
with greenfield plant
Potential Savings $5,208,333-$3,159,453 = $2,048,880
Note that this savings is realized once, during the investment in a greenfield plant.
5.3.4 Financial Analysis
For the financial analysis, I had to make several assumptions, as there are many moving
parts in my model. For example, with the MCSGP the output increases, while with the BioSC
savings are realized through different means. I decided to use the cost of the downstream
purification per gram of drug substance as my financial metric. My assumptions are:
1. The amount of time to process one batch of upstream product is the same. That is, even
if the process is completely continuous, we would expect the fixed costs to be the same as
if they were all batch processes. In other industries, continuous technologies have been
associated with decreased labor and overhead costs, but in this model, I will assume they
will stay the same.
2. There is enough demand so that any increase in yield delivered by MCSGP processes can
be sold.
3. The inventory holding savings are realized on an annual basis.
4. The space savings are only realized once, and only if there is a greenfield plant being
built.
5. There are 40 batches to be made over the year.
Using these assumptions, and then calculating the potential savings for the many different
scenarios, I was able to determine the potential savings. Because the MCSGP process causes
increases in yields, I calculated an annual production cost (includes variable and fixed costs) per
gram, assuming 40 batches per year. I then multiplied that number by the baseline output (when
all the processes are in batch) to get a "normalized" production cost so we can compare
production costs with similar outputs. This is reasonable, as one can imagine for a certain
desired output, with the MCSGP process and its associated higher yield, the plant does not have
to be run for as many batches during the year, lowering the fixed costs appropriately. The
scenarios I have displayed are the baseline (all batch), when only one of the chromatography
steps is either MCSGP or BioSC, when all are MCSGP, and when all are BioSC. Picking these
scenarios allows for the evaluation that follows. Here are the assumptions:
e I used a tubular reactor in all scenarios.
* The scenario shows the sequence of steps, so B-T-B-B means the first chromatography
step is batch, the enzymatic reaction is set as a tubular reactor, the second
chromatography step is batch, and the third chromatography step is batch.
e production cost per gram = [(raw material cost per batch (from model)) *
40 batches per year + fixed costs($10,000,000)] +
(output grams per product per batch * 40 batches per year)
e total annual costs =
normalized production cost per year + inventory holding costs
e normalized production cost = production cost per gram of product *
product output with baseline scenario (all batch processes)
# Scenario: Production "Normalized" Annual Total Annual Savings on
B=batch costs per production inventory annual savings greenfield
CI=MCSGP gram cost per year holding costs from plant
C2=BioSC costs baseline
T=tubular
reactor
I B-T-B-B $2,623/gram $20,185,000 $2,369,940 $22,554,940 -
2 CI-T-B-B $2,309/gram $17,766,818 $2,350,223 $20,117,041 $2,437,899 $680,516
3 C2-T-B-B $2,192/gram $16,870,714 $1,480,797 $18,351,511 $4,203,429 $680,182
4 B-T-Cl-B $1,814/gram $13,956,800 $2,400,183 $16,356,983 $6,197,957 $680,182
5 B-T-C2-B $2,562/gram $19,718,429 $2,290,254 $22,008,683 $546,257 $680,182
6 B-T-B-Cl $2,464/gram $18,962,045 $2,363,540 $21,325,585 $1,229,355 $680,182
7 B-T-B-C2 $2,572/gram $19,791,714 $2,326,897 $22,118,611 $436,329 $680,182
8 Cl-T-C1-C1 $1,496/gram $11,512,235 $2,375,811 $13,888,045 $8,666,895 $2,048,880
9 C2-T-C2-C2 $2,081/gram $16,010,857 $1,358,069 $17,368,926 $5,186,014 $2,052,545
From studying these data, we can come up with the following observations regarding the
two different continuous chromatography technologies:
* When comparing scenario 2 to scenario 3, we see that the latter provides significantly
greater savings. This is because of the following reasons:
o This product already has a high yield of 90%, so increasing the "effective yield"
by 1.75x does not increase the absolute value of the yield significantly.
o The product uses very expensive resin, with an initially low utilization rate. This
means that with the BioSC process, the benefits of the increased resin utilization
are quite significant.
* Scenario 4 has a very significant savings benefit. This is due to the following:
o The yield is very low at 50%. This means that an increase in "effective yield" by
1.75x would be very significant.
o This is further downstream, so the protein product that an increase in yield saves
is more "expensive" than upstream product. Basically, it is more expensive
because it has been processed more.
* The savings associated with scenarios 5 and 7 are significantly lower than the other
scenarios. This is due to the following:
o The resins in these steps are not very expensive, and small quantities are
consumed in each step.
* The savings associated with scenario 8 are greater than that of scenario 9. This is due to
the following:
o The savings associated with the MCSGP process are generally greater than that
with the BioSC process. This is because yield is very important with these
expensive products. If we added the upstream production costs, this difference
would be even more magnified.
These observations lead to the following conclusions:
1. The MCSGP technology is good for low yield steps where the input stream is very
expensive.
2. The BioSC technology is good for processes in which expensive resin is used
inefficiently (low resin utilization).
3. Both processes are good when large volumes of expensive buffer are used.
4. Savings on space can be significant, and should be calculated when a greenfield plant is
being considered.
CHAPTER 6
CONCLUSION
6 Conclusion
From my work at Sandoz Biopharmaceuticals, I am convinced that continuous
chromatography should be explored by innovator and generic companies that want to improve
their current manufacturing methods of biologic molecules. There is clearly a lot of risk - both
financial and regulatory - but the rewards outweigh them. Furthermore, with the increased cost
pressures that are being applied to pharmaceuticals and biologics, it is imperative for companies
to find ways to cut costs to preserve their profit margins. The MCSGP can offer significant
savings, but the risks are significant. Companies must weigh the benefits and risks on a case by
case basis to determine if it makes good business sense to pursue this technology. Conversely,
the BioSC can also impart savings, and it has much less developmental and regulatory risk. It,
too, must be analyzed on an individual basis to determine its applicability to specific products.
Tubular reactors should be used to help make downstream purification processes truly
continuous. As they also confer other advantages, such as better control and potentially lower
residence times, companies need to look at their systems on a case-by-case basis. A more
thorough investigation of this technology would require a separate thesis.
Spray drying offers an alternative to the lyophilization/freeze drying technique that is
currently used in many purification processes. There are some important issues that need to be
determined - yield and product breakdown (proteins subject to intense heat break down in
structure). Sandoz has had mixed results; however I would recommend furthering discussions
with Professor Gerhard Winter at the Ludwig Maximilian University in Munich.
6.1 Biologic X Conclusions
From my work with Biologic X and the MCSGP technology, I was able to make some
very critical observations that support its development. However, first, we must step back and
acknowledge the following facts:
1. This technology is very novel - it is only in laboratory scale size now.
2. There are significant developmental risks associated with upsizing the technology.
3. There are regulatory risks and costs associated with using a new technology to mass-
produce biologics that will be used in humans.
With these conditions, I will now recapitulate and analyze the results I obtained from my
internship:
1. The MCSGP has a significant advantage over other continuous chromatography
technologies because it allows for the increased yield of particular steps. This is
especially beneficial for processes that have a low baseline yield, as modest increases in
yield percent translate to significantly higher absolute yields.
2. As biologics are very expensive to produce (their raw materials, such as resins, can be
costly), increasing yields is particularly attractive.
The results I obtained for Biologic X were very compelling. I was able to show a
significant decrease in COGS of the drug substance, with an eNPV of savings that would justify
the development of this technology, even given its risks. However, if one considers the many
other products in development that could benefit greatly from this technology, the MCSGP
becomes even more attractive. Once the company develops a commercially scaled MCSGP
process for Biologic X (assuming the experiments show significant yield increases with this
molecule), the costs of applying this technology to other products will be much less costly. The
know-how acquired during this process could potentially be used to save much more with other
products.
6.2 Biologic Y Conclusions
From my work with Biologic Y, I was able to study and compare the benefits of the MCSGP
technology and BioSC technology. As the latter does not provide for an increase in product
yield, the potential savings are usually less than that with MCSGP. However, if the initial yield
is already high, the resin costs are high, and the resin utilization is low, then the BioSC process
could impart more cost savings than the MCSGP. In addition, the BioSC process is much more
advanced, and poses less developmental and regulatory risk. So, when the expensive Protein A
resin is used in the purification of monoclonal antibodies, the BioSC process can be used to
impart significant savings. A basic decision tree can be helpful to determine which technology is
more appropriate (see Figure 28).
MCSGP B3o-SC
Consider if: Consider If:
Low yield step Expensive resin
Expensive product Low resin utilization
Downstream Management risk adverse
Figure 28. Decision tree for continuous chromatography
6.3 Management Aspects
Throughout this internship, I had the full support of Dr. Andreas Premstaller, who was
instrumental in helping me get buy-in from the various stakeholders. During the process, I was
able to interact with many different people from across the organization, many of whom were not
aware of my project or familiar with the LGO program. There was initial skepticism from many
parties, which required some careful maneuvering. During the process of talking with these
different stakeholders, I was able to utilize the following techniques that allowed for the success
of my internship.
6.3.1 Recognize the different stakeholders
In a large organization that is as complex as Sandoz and Novartis, it is important to
identify the different stakeholders who would be involved in one's project. I was able to do this
during the first month of my project, which turned out to be critical for the rest of the internship.
I carefully mapped out my project, and then identified all whom could be potentially affected by
my work. Once I met with all of the stakeholders, I started to build credibility.
6.3.2 Build credibility across the different stakeholders
It is important to have a good standing with all of the stakeholders, especially as an
intern. I was able to achieve this by following certain guidelines:
" Be prepared for any meeting - this means doing all the background reading necessary to
sound educated during the meeting. This also showed my stakeholders that I respected
their time.
* When necessary, mention corroboration of important people within the organization. I
did this when I encountered skepticism. Most of the time this technique helped me gain
traction with the person I was meeting with.
" Bring the relevant data, as it is hard to argue with data.
6.3.3 Listen to the stakeholders and learn what metrics are important to them
This technique helped me learn more about my stakeholders, as well as the project. As
many of them had a better working knowledge of the current processes than I had, listening to
them was an educational process. Also, by finding out what metrics they used, I was able to
learn what metrics were important. I then used the data to calculate those metrics to determine
whether the project was worthwhile to them. This was an important step, as I wanted to make
sure that my proposal would genuinely fit with their interests. Fortunately, my data supported
the decision to invest further into the MCSGP technology. In addition, the process of listening
attentively to stakeholders also has the effect of building credibility and a good working
relationship.
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